BioTime, Inc. (BTX) Expected to Announce Quarterly Sales of $710,000.00

Share on StockTwits

Wall Street analysts expect BioTime, Inc. (NASDAQ:BTX) to report sales of $710,000.00 for the current quarter, Zacks reports. Three analysts have provided estimates for BioTime’s earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $1.23 million. BioTime reported sales of $2.55 million in the same quarter last year, which indicates a negative year over year growth rate of 72.2%. The company is expected to report its next quarterly earnings report on Thursday, August 1st.

On average, analysts expect that BioTime will report full-year sales of $3.28 million for the current year, with estimates ranging from $1.20 million to $5.13 million. For the next financial year, analysts expect that the business will post sales of $4.13 million, with estimates ranging from $3.50 million to $5.18 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for BioTime.

BioTime (NASDAQ:BTX) last announced its earnings results on Thursday, May 9th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.36. The business had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.66 million.

Several equities analysts recently commented on BTX shares. HC Wainwright reiterated a “buy” rating on shares of BioTime in a report on Thursday, February 21st. Dawson James reiterated a “buy” rating on shares of BioTime in a report on Thursday, February 7th.

Shares of NASDAQ BTX traded down $0.02 during mid-day trading on Friday, hitting $1.11. 1,651 shares of the company’s stock traded hands, compared to its average volume of 872,433. BioTime has a 1 year low of $0.66 and a 1 year high of $2.81.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

See Also: What is a dead cat bounce?

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with's FREE daily email newsletter.